dr. west on considering factors for egfr tkis in nsclc
Published 7 years ago • 121 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
0:59
dr. west on emerging changes in the field of egfr-mutant nsclc
-
1:47
dr. west on fda approval of afatinib in nsclc with rare egfr mutations
-
5:47
egfr tkis for upfront treatment of nsclc
-
3:14
dr. west on fda approval of frontline osimertinib in egfr nsclc
-
0:40
copy of dr. west on fda approval of frontline osimertinib in egfr nsclc
-
1:27
dr. wakelee discusses egfr tkis in lung cancer
-
1:57
dr. piotrowska on treatment for egfr-mutant nsclc
-
2:36
second- and third-generation tkis in egfr-mutated nsclc
-
1:36
dr. heather wakelee on what to do when resistance to egfr tkis emerges
-
2:07
dr. west on advancements for patients with t790m-mutant nsclc
-
28:17
segment 1: egfr tkis in nsclc
-
20:24
targeted treatment with egfr tkis: front line options
-
2:14
dr. yang on osimertinib as first-line therapy for egfr-positive nsclc
-
2:45
activity of egfr tkis in patients with nsclc with uncommon egfr mutations
-
1:47
dr. scagliotti on mechanisms of resistance to egfr tkis
-
9:30
egfr testing for nsclc
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
5:45
egfr tki sequencing
-
2:10
reconsideration of gefitinib in egfr-mutant nsclc